HomeCompareNPPNY vs ABBV

NPPNY vs ABBV: Dividend Comparison 2026

NPPNY yields 2.84% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NPPNY wins by $56.0K in total portfolio value· pulled ahead in Year 8
10 years
NPPNY
NPPNY
● Live price
2.84%
Share price
$7.40
Annual div
$0.21
5Y div CAGR
47.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$158.3K
Annual income
$65,881.22
Full NPPNY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NPPNY vs ABBV

📍 NPPNY pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNPPNYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NPPNY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NPPNY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NPPNY
Annual income on $10K today (after 15% tax)
$241.22/yr
After 10yr DRIP, annual income (after tax)
$55,999.04/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NPPNY beats the other by $34,943.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NPPNY + ABBV for your $10,000?

NPPNY: 50%ABBV: 50%
100% ABBV50/50100% NPPNY
Portfolio after 10yr
$130.3K
Annual income
$45,326.49/yr
Blended yield
34.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NPPNY
No analyst data
Altman Z
6.7
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NPPNY buys
0
ABBV buys
0
No recent congressional trades found for NPPNY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNPPNYABBV
Forward yield2.84%3.06%
Annual dividend / share$0.21$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR47.7%40.6%
Portfolio after 10y$158.3K$102.3K
Annual income after 10y$65,881.22$24,771.77
Total dividends collected$128.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NPPNY vs ABBV ($10,000, DRIP)

YearNPPNY PortfolioNPPNY Income/yrABBV PortfolioABBV Income/yrGap
1$11,119$419.15$11,550$430.00$431.00ABBV
2$12,541$643.33$13,472$627.96$931.00ABBV
3$14,420$1,001.58$15,906$926.08$1.5KABBV
4$17,019$1,589.76$19,071$1,382.55$2.1KABBV
5$20,801$2,590.00$23,302$2,095.81$2.5KABBV
6$26,626$4,369.50$29,150$3,237.93$2.5KABBV
7$36,211$7,720.76$37,536$5,121.41$1.3KABBV
8← crossover$53,240$14,493.90$50,079$8,338.38+$3.2KNPPNY
9$86,382$29,415.55$69,753$14,065.80+$16.6KNPPNY
10$158,310$65,881.22$102,337$24,771.77+$56.0KNPPNY

NPPNY vs ABBV: Complete Analysis 2026

NPPNYStock

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

Full NPPNY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NPPNY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NPPNY vs SCHDNPPNY vs JEPINPPNY vs ONPPNY vs KONPPNY vs MAINNPPNY vs JNJNPPNY vs MRKNPPNY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.